脑脊液中的神经丝重链NfH(SMI35)有助于帕金森综合征的鉴别诊断。
Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
作者信息
Brettschneider Johannes, Petzold Axel, Süssmuth Sigurd D, Landwehrmeyer Georg B, Ludolph Albert C, Kassubek Jan, Tumani Hayrettin
机构信息
Department of Neurology, University of Ulm, Ulm, Germany.
出版信息
Mov Disord. 2006 Dec;21(12):2224-7. doi: 10.1002/mds.21124.
We aimed to evaluate the potential of the cerebrospinal fluid (CSF) axonal damage biomarker NfH(SMI35) in the laboratory-supported differential diagnosis of parkinsonian syndromes. Patients with idiopathic Parkinson's disease (PD; n = 22), multiple-system atrophy (MSA; n = 21), progressive supranuclear palsy (PSP; n = 21), corticobasal degeneration (CBD; n = 6), and age-matched controls (n = 45) were included. CSF levels of NfH(SMI35) were measured using ELISA. Levels of CSF NfH(SMI35) were elevated in PSP compared to PD and controls (P < 0.05 each). They were also significantly higher in MSA than in PD and controls (P < 0.05 each). NfH(SMI35) differentiated PD from PSP with a sensitivity of 76.5% and a specificity of 94.4%. Axonal damage as measured by CSF NfH(SMI35) is most prominent in the more rapidly progressive syndromes PSP and MSA as compared to PD or CBD. CSF NfH(SMI35) may therefore be of some value for the laboratory-supported differential diagnosis of atypical parkinsonian syndromes.
我们旨在评估脑脊液（CSF）轴突损伤生物标志物神经丝蛋白H（NfH，单克隆抗体SMI35识别表位）在帕金森综合征实验室辅助鉴别诊断中的潜力。纳入特发性帕金森病（PD；n = 22）、多系统萎缩（MSA；n = 21）、进行性核上性麻痹（PSP；n = 21）、皮质基底节变性（CBD；n = 6）患者以及年龄匹配的对照组（n = 45）。采用酶联免疫吸附测定（ELISA）法检测脑脊液中NfH（SMI35）水平。与PD患者及对照组相比，PSP患者脑脊液NfH（SMI35）水平升高（均P < 0.05）。MSA患者脑脊液NfH（SMI35）水平也显著高于PD患者及对照组（均P < 0.05）。NfH（SMI35）鉴别PD与PSP的敏感度为76.5%，特异度为94.4%。与PD或CBD相比，通过脑脊液NfH（SMI35）检测到的轴突损伤在进展更快的综合征PSP和MSA中最为突出。因此，脑脊液NfH（SMI35）可能对非典型帕金森综合征的实验室辅助鉴别诊断具有一定价值。
Zotero 插件